{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:05:48Z","timestamp":1773205548615,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/LCG\/004\/2018"],"award-info":[{"award-number":["NMRC\/LCG\/004\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.oret.2019.10.019","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T23:22:37Z","timestamp":1573255357000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-7604","authenticated-orcid":false,"given":"Beau J.","family":"Fenner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.W.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna C.S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7081","authenticated-orcid":false,"given":"Kelvin","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choi Mun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian Y.S.","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund Y.M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.10.019_bib1","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.oret.2019.10.019_bib2","first-page":"335","article-title":"Role of vascular endothelial growth factor in ocular angiogenesis","volume":"19","author":"Shams","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"issue":"10 Suppl","key":"10.1016\/j.oret.2019.10.019_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration","volume":"22","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0161-6420(03)00085-X","article-title":"Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.10.019_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004015","article-title":"A\u00a0comparison of the causes of blindness certifications in England and Wales in working age adults (16\u201364 years), 1999\u20132000 with 2009\u20132010","volume":"4","author":"Liew","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.oret.2019.10.019_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/eye.2014.296","article-title":"Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom","volume":"29","author":"Buckle","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.10.019_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101072","article-title":"Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment","volume":"9","author":"Mitchell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2019.10.019_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajo.2011.08.035","article-title":"Time trends in the incidence and causes of blindness in Israel","volume":"153","author":"Skaat","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archophthalmol.2011.140","article-title":"Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration","volume":"129","author":"Bressler","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/eye.2015.83","article-title":"Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland","volume":"29","author":"Borooah","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.10.019_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.10.019_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.10.019_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"IVAN Study Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A\u00a0variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.10.019_bib27","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.10.019_bib28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5301\/ejo.5000385","article-title":"One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting","volume":"24","author":"Gabai","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib30","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2019.10.019_bib33","first-page":"488","article-title":"The ARMOUR study: anti-VEGF in neovascular AMD\u2014our understanding in a real-world Indian setting","volume":"6","author":"Jain","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.oret.2019.10.019_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2415-13-10","article-title":"Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up","volume":"13","author":"Matsumiya","year":"2013","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10384-014-0333-5","article-title":"Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration","volume":"58","author":"Nomura","year":"2014","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101057","article-title":"A\u00a0prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"9","author":"Cheung","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2019.10.019_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.oret.2018.11.003","article-title":"A\u00a0multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy","volume":"3","author":"Teo","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib39","first-page":"1802","article-title":"One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study","volume":"11","author":"Chen","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib40","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/OPTH.S178228","article-title":"Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences","volume":"12","author":"Ratanasukon","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archopht.1991.01080090066027","article-title":"Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Koh","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib43","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2019.10.019_bib44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2019.10.019_bib45","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.1038\/s41598-018-25864-0","article-title":"Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan","volume":"8","author":"Chang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2019.10.019_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/OPX.0000000000000283","article-title":"Trends in age-related macular degeneration management in Singapore","volume":"91","author":"Ng","year":"2014","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.oret.2019.10.019_bib47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.10.019_bib48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/eye.2011.324","article-title":"Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"Cho","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.10.019_bib49","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.10.019_bib50","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1038\/s41598-019-38934-8","article-title":"Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment","volume":"9","author":"Wecker","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2019.10.019_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment burden in neovascular AMD: visual acuity outcomes are associated with anti-VEGF injection frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2019.10.019_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ophtha.2008.10.029","article-title":"Economic implications of current age-related macular degeneration treatments","volume":"116","author":"Smiddy","year":"2009","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019306256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019306256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:27:25Z","timestamp":1762853245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653019306256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S2468653019306256"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.10.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}